Osteosarkom
Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.
| ID | DIS-OSTEOSARCOMA |
|---|---|
| Art | Erkrankung |
| Aliase | Herkömmliches OsteosarkomOSOsteogenes SarkomОстеосаркома |
| Status | reviewed 2026-05-19 | pending_clinical_signoff |
| Erkrankungen | None declared |
| Quellen | SRC-ESMO-BONE-SARCOMA SRC-NCCN-BONE-SARCOMA SRC-NCCN-PEDIATRIC-SARCOMA |
Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.
| icd_o_3_morphology | 9180/3 |
|---|---|
| icd_o_3_topography | ["C40", "C41"] |
| icd_10 | C40, C41 |
| who_classification | WHO Weichgewebe und Knochentumore 5 ed (2020): Osteosarkom — konventionelles (hochgradiges intramedulläres), telangiektatisches, kleines Zellgewebe, mittelgradiges, parosteales, periosteales, hochgradiges Oberflächenmaterial, extraskelettales |
Anmerkungen
Osteosarcoma is the most common primary malignant bone tumor in children + adolescents. Bimodal age distribution: adolescent growth-spurt peak (10–20y; long-bone metaphyses) and elderly secondary peak (>60y; predominantly Paget disease-associated or post-radiation). Standard-of-care multi-modal treatment (full Indications pending): neoadjuvant chemotherapy → en-bloc surgical resection (limb-salvage preferred; amputation reserved for unresectable / vascular-bundle invasion) → adjuvant chemotherapy. MAP regimen (high-dose methotrexate, doxorubicin, cisplatin) is the global standard from EURAMOS-1 (good-responder arm). Histological necrosis ≥90% at resection predicts favorable outcome; poor responders (<90% necrosis) do NOT benefit from intensification per EURAMOS-1. Genetic relationships drive prevention-workstream surveillance: - Li-Fraumeni (germline TP53): osteosarcoma is the second-most common cancer in this syndrome; Toronto-protocol annual whole-body MRI + bone surveillance recommended. v0.2-B pilot. - Hereditary retinoblastoma (germline RB1) survivors: lifetime osteosarcoma risk markedly elevated, particularly within prior RT field. Long-term surveillance post-retinoblastoma...
Verwendet von
Algorithmen
ALGO-CASCADE-LFS-CARRIER-FAMILY-TESTING- ALGO-CASCADE-LFS-CARRIER-FAMILY-TESTINGALGO-CHOMPRET-2015-LFS- ALGO-CHOMPRET-2015-LFSALGO-STS-ADVANCED-1L- ALGO-STS-ADVANCED-1L
Erkrankung
DIS-CHOROID-PLEXUS-CARCINOMA- ChoroidplexuskarzinomDIS-RETINOBLASTOMA- RetinoblastomDIS-RHABDOMYOSARCOMA- Rhabdomyosarkom
Anwendungsgebiet
IND-ROTHMUND-THOMSON-CARRIER-INTENSIFIED- IND-ROTHMUND-THOMSON-CARRIER-INTENSIFIEDIND-ROTHMUND-THOMSON-CARRIER-SURVEILLANCE- IND-ROTHMUND-THOMSON-CARRIER-SURVEILLANCE
Warnhinweis
RF-IATROGENIC-PRIOR-RADIATION-PREVENTION- Geschichte der therapeutischen Strahlenexposition ≥ 5 Jahren zu einem Körperbereich — am häufigsten m...RF-LI-FRAUMENI-CONFIRMED-CARRIER- Patient hat eine bestätigte keimlinien-TP53-pathogene Variante (positive keimlinien-Test, distinc...RF-ROTHMUND-THOMSON-CONFIRMED-CARRIER- Bestätigte biallelic keimlinien-pathogene / wahrscheinlich-pathogene Varianten in RECQL4 (RecQ-ähnliche...RF-WERNER-CONFIRMED-CARRIER- Bestätigte biallelic keimlinien-pathogene / wahrscheinlich-pathogene Varianten in WRN (RECQL2; Wern...